布地奈德联合氨茶碱治疗老年慢性阻塞性肺疾病患者的临床效果及安全性观察

在线阅读 下载PDF 导出详情
摘要   【摘 要】目的:探讨布地奈德联合氨茶碱治疗老年慢性阻塞性肺疾病的疗效及安全性。 方法:选择 2018年 4月至 2019年 4月在我院治疗的 80例慢性阻塞性肺疾病患者,将所有患者按照随机数字表法随机分为观察组和对照组,每组患者数量均为 40例。观察组患者给予布地奈德吸入,同时加用氨茶碱口服。对照组仅给予布地奈德吸入,吸入方法同观察组。在治疗 3个月后,使用肺功能仪检测两组老年慢性阻塞性肺疾病患者的测定第一秒用力呼气容积 ( FEV1/FVC)、 用力肺活量 ( FVC),观察临床症状等情况以评价治疗效果,并记录两组患者的不良反应事件发生情况。结果:两组患者治疗前后肺功能情况对比,观察组和对照组治疗前第一秒用力呼气容积 ( FEV1/FVC)、 用 力肺活量 ( FVC)对比差异无统计学意 义( P>0.05); 观察组 患者治疗后 FEV1/FVC和 FVC水平与对照组有明显改善,对比差异具有统计学意义( P<0.05)。观察组患者总有效率为 92.5%;对照组患者总有效率 82.5%;两组患儿临床治疗总有效率对比差异具有统计学差异( P<0.05)。观察组患者不良反应发生率为 6.25%;对照组患者不良反应发生率 6.1%;两组患者之间不良事件发生率对比无统计学意义( P>0.05)。结论:布地奈德联合氨茶碱治疗老年慢性阻塞性肺疾病治疗效果优于单用布地奈德,且并未增加不良事件发生率,值得临床应用。    【关键词】布地奈德;氨茶碱;慢性阻塞性肺疾病;临床效果;安全性     Objective: To investigate the efficacy and safety of budesonide combined with aminophylline in the treatment of elderly patients with chronic obstructive pulmonary disease. Methods: 80 patients with chronic obstructive pulmonary disease in our hospital from April 2018 to April 2019 were selected and randomly divided into observation group and control group according to random number table method, with 40 cases in each group. Patients in the observation group were given budesonide inhalation and aminophylline orally. The control group was only given budesonide inhalation, and the inhalation method was the same as that of the observation group. After 3 months of treatment, the first second forced expiratory volume (FEV1 / FVC) and forced vital capacity (FVC) were measured by pulmonary function instrument in the two groups of elderly patients with chronic obstructive pulmonary disease. The clinical symptoms were observed to evaluate the treatment effect, and the incidence of adverse reactions was recorded in the two groups. Results: there was no significant difference in forced expiratory volume (FEV1 / FVC) and forced vital capacity (FVC) in the first second before treatment between the observation group and the control group (P > 0.05); after treatment, the levels of FEV1 / FVC and FVC in the observation group were significantly improved compared with those in the control group (P < 0.05). The total effective rate of the observation group was 92.5%; the total effective rate of the control group was 82.5%; the difference between the two groups was statistically significant (P < 0.05). The incidence of adverse reactions in the observation group was 6.25%; the incidence of adverse reactions in the control group was 6.1%; there was no significant difference in the incidence of adverse events between the two groups (P > 0.05). Conclusion: the effect of budesonide combined with aminophylline in the treatment of elderly patients with chronic obstructive pulmonary disease is better than that of budesonide alone, and does not increase the incidence of adverse events, which is worthy of clinical application.
作者 王莹
出处 《中华医学信息导报》 2020年9期
关键词
出版日期 2020年09月12日(中国期刊网平台首次上网日期,不代表论文的发表时间)